CogState (CGS.AX) Aksje Kurs
CogState Kurs
De siste 19 årene vokste omsetningen til CogState med 20,0 % årlig og nådde 53,09 M USD. Resultat per aksje har vokst med 8,5 % i året de siste 16 årene. For CogState er nettomargin på 19,1 % opp sammenlignet med 16,0 % for noen år siden. Til dagens kurs blir direkteavkastningen om lag 1,21 %. Utbetalingsgraden er rundt 34 % av overskuddet. Konsensus 12-måneders kursmål for CogState er 2,17 USD, om lag under kursen med 8,4 %. Av 6 analytikere anbefaler 5 kjøp — den samlede vurderingen er Kjøp.
CogState aksjekurs
Hent disse dataene via Eulerpool API
100 000 kall/mnd gratis · ingen kredittkort
CogState forretningsmodell & aksjeanalyse
Ofte stilte spørsmål om CogState
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analytikere setter for øyeblikket et gjennomsnittlig kursmål på 2,17 USD for CogState-aksjen (median: 2,17 USD), noe som innebærer −8,4 % mot siste kurs. Konsensus er basert på 6 analytikervurderinger.
7 analytikere vurderer for øyeblikket CogState-aksjen: 6 anbefaler kjøp, 1 hold og 0 salg. For 2026 forventer analytikere at CogState genererer omsetning på 128,65 M USD og resultat per aksje på 0,09 USD.
Omregnet til gjeldende valutakurs handles CogState-aksjen til 2,12 EUR (2,37 USD).
CogState-aksjen (CGS.AX) er notert på 2 børser, blant annet: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
forventet omsetningen for CogState er 128,65 M USD. Denne verdien er basert på nåværende regnskapstall og gjenspeiler selskapets forretningsutvikling.
forventet gevinsten for CogState er 16,22 M USD. Nettoresultatet viser selskapets lønnsomhet etter fradrag av alle kostnader.
Pris-til-inntjening-ratioen (P/E) for CogState er for tiden 25,40. P/E-ratioen sammenligner dagens aksjekurs med inntjening per aksje og hjelper investorer med å vurdere verdisetningen av CogState-aksjen.
Pris-til-salg-ratioen (P/S) for CogState er for tiden 3,20. P/S-ratioen sammenligner markedskapitalisering med årlig omsetning og fungerer som en verdisettelsesindiktor for CogState-aksjen.
Eulerpool Quality Score for CogState er 8/10.
ISIN for CogState er AU000000CGS8. ISIN (International Securities Identification Number) er en globalt unik identifikator for verdipapirer.
Tickeren for CogState er CGS.AX. Tickersymbolet brukes til å handle CogState-aksjer på børsen.
CogState aksje
CogState Peer Group
CogState Ticker
CogState FIGI
Alle nøkkeltall og dypere analyse av CogState
Vår aksjeanalyse av CogState-aksjen inneholder viktige finansielle nøkkeltall som omsetning, fortjeneste, P/E-forholdet, P/S-forholdet, EBIT, samt informasjon om utbyttet. Vi ser også på aspekter som antall aksjer, markedsverdi, gjeld, egenkapital og forpliktelser hos CogState. Hvis du er på utkikk etter mer detaljert informasjon om disse emnene, tilbyr vi deg utfyllende analyser på våre undersider: